Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy – Observational prospective single institution analysis

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

(2019) Sigbjørn Smeland et al.   EUROPEAN JOURNAL OF CANCER

Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma

(2019) Caroline Brard et al.   BMJ Open

The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma

(2018) Nurdan Tacyildiz et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments

(2013) P.M. Anderson et al.   PEDIATRIC BLOOD & CANCER

Review of mifamurtide in the treatment of patients with osteosarcoma

(2010) Leo Kager et al.   Therapeutics and Clinical Risk Management

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma

(2009) Alexander J. Chou et al.   CANCER